11-86954989-G-A
Variant summary
Our verdict is Benign. Variant got -18 ACMG points: 2P and 20B. PM1BP4_StrongBP6_Very_StrongBS1BS2
The NM_012193.4(FZD4):c.97C>T(p.Pro33Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0174 in 1,612,504 control chromosomes in the GnomAD database, including 322 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_012193.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FZD4 | NM_012193.4 | c.97C>T | p.Pro33Ser | missense_variant | 1/2 | ENST00000531380.2 | NP_036325.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FZD4 | ENST00000531380.2 | c.97C>T | p.Pro33Ser | missense_variant | 1/2 | 1 | NM_012193.4 | ENSP00000434034 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0126 AC: 1909AN: 152074Hom.: 17 Cov.: 32
GnomAD3 exomes AF: 0.0169 AC: 4093AN: 242758Hom.: 73 AF XY: 0.0155 AC XY: 2066AN XY: 132932
GnomAD4 exome AF: 0.0179 AC: 26069AN: 1460314Hom.: 304 Cov.: 33 AF XY: 0.0173 AC XY: 12569AN XY: 726526
GnomAD4 genome AF: 0.0126 AC: 1913AN: 152190Hom.: 18 Cov.: 32 AF XY: 0.0122 AC XY: 910AN XY: 74406
ClinVar
Submissions by phenotype
not provided Benign:4
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2023 | FZD4: BS1, BS2 - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Dec 21, 2018 | This variant is associated with the following publications: (PMID: 21179236, 28982955, 24744206, 27535533, 15733276, 15223780, 22995991) - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Exudative vitreoretinopathy 1 Benign:3
Likely benign, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 29, 2022 | - - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Mar 06, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Benign, criteria provided, single submitter | research | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | - | The heterozygous p.Pro33Ser variant in FZD4 has been identified in an individual with exudative vitreoretinopathy (PMID: 15733276), but has been identified in >4% of Latino chromosomes and 39 total homozygotes by ExAC (http://gnomad.broadinstitute.org/). In summary, this variant meets criteria to be classified as benign for autosomal dominant exudative vitreoretinopathy. - |
not specified Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 29, 2016 | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Frequency in ESP (all): 150/12934=1.15% - |
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Oct 28, 2014 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at